One of the most significant challenges in breast cancer treatment is the limited efficacy of ICIs, such as anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapies. The gene discussed is CTLA4; the disease is breast cancer.